Sobanski M A, Vince R, Biagini G A, Cousins C, Guiver M, Gray S J, Kaczmarski E B, Coakley W T
School of Biosciences, Cardiff University, Cardiff CF10 3TL, UK.
J Clin Pathol. 2002 Jan;55(1):37-40. doi: 10.1136/jcp.55.1.37.
To examine A, C, Y, and W135 Neisseria meningitidis serogroup characterisation by ultrasonic standing wave enhanced latex agglutination tests (USELATs) of clinical samples. In addition, to determine USELAT enhancement of detection sensitivity for the individual antigens compared with conventional card latex agglutination tests (LATs).
Wellcogen (Abbott Murex), Slidex meningite kit 5 (bioMerieux), and Pastorex (Sanofi) kits and beads coated in house with antibodies to Y and to W135 alone were tested. Positive control antigens consisted of A and C polysaccharide preparations and the Pastorex Y/W135 kit sample. The limiting concentrations of antigen detection were determined by USELAT and by LAT. Thirty five clinical samples (plasma), previously characterised by the polymerase chain reaction (PCR) and culture, were tested by USELAT and, when sample volume allowed, by LAT.
USELAT enhancement of control antigen detection ranged from 16 to 128 fold for the different latex systems. Enhancements for the different control antigens were comparable between kits. USELAT tests of clinical (A/C/Y/W135) samples (n = 15) with the Wellcogen (A/C/Y/W135) and Slidex meningite (A/C/Y/W135) kits showed comparable specificities. A set (n = 22) of Y and W135 samples gave 18, 19, and 17 positive results for Wellcogen (A/C/Y/W135), Pastorex (A/C/Y/W135), and in house beads (Y/W135), respectively. Positive USELAT PCR and culture results were concordant. A typical sensitivity for the commercial kits was 80% (Wellcogen).
USELAT identified serogroups for 80% of samples, whereas LATs identified only 40%. The USELAT detection of the A, C, Y, and W135 antigen serogroups showed comparable enhancement for the kits tested. The commercial availability of latex beads coated with antibody to the Y and W135 serogroups would expedite their identification.
通过对临床样本进行超声驻波增强乳胶凝集试验（USELAT）来检测A、C、Y和W135群脑膜炎奈瑟菌血清型特征。此外，与传统的卡片乳胶凝集试验（LAT）相比，确定USELAT对各个抗原检测灵敏度的增强效果。
对Wellcogen（雅培美时）、Slidex脑膜炎试剂盒5（生物梅里埃）、Pastorex（赛诺菲）试剂盒以及自行制备的仅包被有抗Y和抗W135抗体的珠子进行检测。阳性对照抗原包括A和C多糖制剂以及Pastorex Y/W135试剂盒样本。通过USELAT和LAT确定抗原检测的极限浓度。对35份先前经聚合酶链反应（PCR）和培养鉴定的临床样本（血浆）进行USELAT检测，样本量允许时也进行LAT检测。
对于不同的乳胶系统，USELAT对对照抗原检测的增强倍数在16至128倍之间。不同试剂盒对不同对照抗原的增强效果相当。使用Wellcogen（A/C/Y/W135）和Slidex脑膜炎（A/C/Y/W135）试剂盒对临床（A/C/Y/W135）样本（n = 15）进行USELAT检测，显示出相当的特异性。一组（n = 22）Y和W135样本中，Wellcogen（A/C/Y/W135）、Pastorex（A/C/Y/W135）和自行制备的珠子（Y/W135）分别给出18、19和17个阳性结果。USELAT、PCR和培养的阳性结果一致。商业试剂盒的典型灵敏度为80%（Wellcogen）。
USELAT可鉴定80%样本的血清型，而LAT仅能鉴定40%。USELAT对A、C、Y和W135抗原血清型的检测对所测试的试剂盒显示出相当的增强效果。包被有抗Y和W135血清型抗体的乳胶珠子的商业可得性将加快其鉴定。
